Loading...
•
Mar 31, 2024
Generation Bio Q1 2024 Earnings Report
Generation Bio reported first quarter 2024 financial results and provided updates on its ctLNP and iqDNA platforms.
Key Takeaways
Generation Bio reported a net loss of $74.5 million for Q1 2024. The company's cash, cash equivalents, and marketable securities totaled $233.9 million, expected to fund operations into the second half of 2027. The company presented new data on its ctLNP and iqDNA platforms.
Presented data at ASGCT on cell-targeted lipid nanoparticle (ctLNP) platform.
Disclosed new information about iqDNA platform and RES at ASGCT.
Cash, cash equivalents, and marketable securities were $233.9 million as of March 31, 2024.
Company believes cash will fund operations into 2H 2027.
Generation Bio
Generation Bio
Generation Bio Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
The company continues to believe that its cash, cash equivalents, and marketable securities will fund its operating plan into the second half of 2027.